Q-omics provides the consensus-scored ANKRD35 profile across patient tissues and cancer cell-line models. ANKRD35 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ANKRD35 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ANKRD35 RNA expression shows 13,963 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, HNSC, and THYM as cancer lineages where ANKRD35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD35 survival associations across molecular data types. ANKRD35 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD35 RNA expression–survival associations across cancer types. High ANKRD35 expression shows unfavorable associations in KIRP and LGG, but favorable associations in CESC, HNSC, CHOL and UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRP as the clearest survival context for ANKRD35 RNA expression.
This table summarizes ANKRD35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD35 shows lower tumor expression in HNSC, KICH, THCA, BLCA, COAD and STAD. The HNSC box plot shows higher ANKRD35 RNA expression in normal versus tumor tissue (log2 FC = −2.345, t-test p < 0.001).
This table shows molecular features associated with ANKRD35 in patient tissues and cancer cell lines. In patient samples, ANKRD35 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD35 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
